van der Fits, L., van der Wel, L.I., Laman, J.D., et al. (2004) In psoriasis lesional skin the type I interferon signaling pathway is activated, whereas interferon-alpha sensitivity is unaltered. Journal of Investigative Dermatology, 122, 51-60. doi:10.1046/j.0022-202X.2003.22113.x

has been cited by the following article:

• TITLE: Psoriatic skin lesions induced by tumor-necrosis-factor-alpha-therapy

  AUTHORS: Antonia Cosima Faul, Christian Folwaczny, Birgit Angela Aigner, Rüdiger Hein, Johannes Ring, Sabine Gisela Plötz

  KEYWORDS: Infliximab; Psoriasis; TNFα Inhibitors; Crohn’s Disease; Ankylosing Spondylitis; Side Effects

  JOURNAL NAME: Case Reports in Clinical Medicine, Vol.2 No.1, March 25, 2013

  ABSTRACT: A 46-year-old, caucasian woman suffering from Crohn’s disease and a 35-year-old woman suffering from ankylosing spondylitis were treated with the TNFα blocker infliximab and developed psoriasiform skin lesions. The pathophysiology of this paradoxical clinical response as a newly recognized adverse effect of TNFα antagonists is unknown. According to the literature, this type of newly triggered psoriasis may occur any time after initiation of TNFα antagonist therapy and responds to classic antipsoriatic treatment. The phenomenon warrants attention, especially when considering anti-TNFα treatment in various skin diseases besides psoriasis.